Schering-Plough taps China innovation through HUYA
This article was originally published in Scrip
Schering-Ploughis looking to access China's growing innovative capability through a tie-up with HUYA Bioscience International. HUYA will exclusively provide to the US major's Organon subsidiary drug development candidates sourced from its network of Chinese research alliances.
You may also be interested in...
US pharma giant joins Singapore alliance aiming to encourage regional startups and innovation, in multiple tech-related areas including digital health, through the provision of expertise and support.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
AbbVie Japan has seen strong growth for its commercial and R&D portfolios over the past few years, but with flagship product Humira facing its first local biosimilar competition, the company is looking to brand strength and an increased oncology presence to address the challenge.